Uveal Tumors

This is a general term for any abnormal growth or tumor found in the uvea, the middle layer of the eye. These can be benign (not cancerous) or malignant (cancerous).

Condition

What people with Uveal Tumors report

Every report comes from a Lived member, sent anonymously.

Have you had Brachytherapy for Uveal Tumors?

NameHow it went

About Uveal Tumors

What It Is

Uveal tumors are growths that form in the uvea, the middle layer of the eyeball. The uvea has three parts: the iris (the colored ring at the front of the eye), the ciliary body (a ring of muscle behind the iris that helps the eye focus) and the choroid (a layer of blood vessels at the back of the eye that nourishes the retina). Because most of the uvea sits inside the eye, these tumors usually can't be seen in a mirror and are often found during a routine dilated eye exam. The term covers very different growths, so the first question is always which kind is present. The most common is a choroidal nevus, a flat, freckle-like spot of pigment cells at the back of the eye. Nevi are found in about 1 in 20 American adults and are benign; only a very small number ever turn into cancer. The most important cancer that starts in the uvea is uveal melanoma, which grows from the same kind of pigment-making cells. It is rare, but it is the most common cancer that begins inside the eye in adults. Lymphoma can also start in the eye, and cancers from elsewhere in the body, most often the breast or lung, can spread to the uvea. Together, these spread cancers are more common than cancers that start in the eye. Many uveal tumors cause no symptoms. When they do, the usual signs are blurred or distorted vision, a shadow or missing area in the field of sight, floaters or flashes of light, a dark spot on the iris that grows, or a change in the shape of the pupil. Pain is uncommon.

Causes & Risk Factors

For most people, there is no single identifiable reason a uveal tumor develops. For uveal melanoma, the best-established risk factors are fair skin that burns or freckles easily, light-colored eyes such as blue, green or gray, and older age. It is far more common in White people and slightly more common in men. Having a nevus in the eye, or ocular melanocytosis (extra pigment in and around the eye, sometimes called nevus of Ota), also raises the risk. Even so, most people with these features never develop eye cancer, and some people with none of them do. A small share of cases runs in families. BAP1 tumor predisposition syndrome, caused by an inherited change in the BAP1 gene, raises the risk of uveal melanoma along with skin melanoma, mesothelioma, kidney cancer and some other cancers, often at younger ages. A family history of several of these cancers is worth raising with a doctor. Welding, which exposes the eyes to intense ultraviolet light, has also been linked to higher risk. Unlike skin melanoma, uveal melanoma has not been clearly tied to sunlight; studies are mixed, and any added risk appears small. Tumors that spread to the eye from elsewhere share the risk factors of the cancer they came from.

How It's Diagnosed

Most uveal tumors are diagnosed by an eye specialist examining and measuring the tumor directly, without needing to remove tissue. During a dilated eye exam, drops widen the pupil so the doctor can see the back of the eye with a bright light and magnifying lenses. Photographs record the tumor's appearance so that later visits can show whether it is growing. Imaging adds detail. An ultrasound of the eye, done with a small probe placed gently on the numbed eye, measures the tumor's thickness and shows its internal pattern. Optical coherence tomography (OCT), a light-based scan, shows whether fluid has collected under the retina, and dye tests called angiography show the tumor's blood vessels. Together, these findings help separate a harmless nevus from an early melanoma. Thickness over about 2 millimeters, fluid under the retina, orange pigment on the surface, a wide base and symptoms such as blurred vision each make growth into melanoma more likely, and a spot with several of these features is watched closely or treated. A biopsy, in which a fine needle removes a few cells, is rarely needed to make the diagnosis. It may be done when the picture is unclear or to test the tumor's genes, and it carries a small risk of retinal detachment, which can be repaired with surgery. Gene tests on melanoma cells estimate how likely the cancer is to spread in the future, which helps set how closely someone is followed afterward. If melanoma is confirmed, staging tests look for spread beyond the eye. Because uveal melanoma usually spreads first to the liver, these focus on liver blood tests and imaging such as ultrasound, CT or MRI.

Treatment Options

Treatment depends on what the tumor is, where it sits, how large it is and whether it has spread. A typical choroidal nevus needs no treatment, only periodic checks with photographs to confirm it isn't changing. Lymphoma in the eye and cancers that have spread to the eye are treated as part of care for that cancer. For uveal melanoma that is still confined to the eye, the goals are to control the tumor, keep the eye when possible and preserve as much vision as the tumor's location allows. Radiation is the most common treatment. In plaque brachytherapy, a small disc lined with radioactive seeds is stitched to the outside of the eye over the tumor, left for several days and then removed in a second short operation. It stops the tumor growing in the eye in about 9 in 10 small and medium tumors. Controlling the tumor in the eye does not by itself remove the risk of later spread, which is why follow-up continues for years after treatment. Proton beam therapy, a tightly focused beam from outside the body, is often used when a plaque can't cover the tumor, such as a large tumor or one near the optic nerve, but only some centers offer it. Radiation works gradually: the tumor shrinks slowly over months or longer, and repeat eye exams and ultrasound show how it is responding. Its main trade-off is damage to the eye over time, including cataract, dry eye, glaucoma and retinal problems, which can reduce vision even when the cancer is controlled. Some very small tumors that are hard to tell from a nevus are watched closely and treated only if they grow. Laser heat treatment is sometimes added after radiation. Surgery ranges from removing only the tumor to removing the whole eye (enucleation), which is generally reserved for very large tumors, painful eyes or eyes that have already lost useful vision. For medium-sized melanomas, radiation and surgery appear to be about equally effective, so the choice turns on vision, appearance and the tumor's features. After enucleation, a custom artificial eye is fitted to match the other eye. When uveal melanoma has spread, treatment aims to control the cancer and extend life rather than cure it. Tebentafusp (Kimmtrak) is an immunotherapy that links the body's T cells, a type of immune cell, to melanoma cells so they can attack them. It is approved for adults with a specific tissue type, HLA-A*02:01, which a blood test identifies, and is given as a weekly infusion into a vein. Because it can set off cytokine release syndrome, an intense immune reaction that can be serious, the first three infusions are given with overnight monitoring in a healthcare setting. Other options include treatments aimed directly at the liver, such as surgery to remove liver tumors or treatment delivered through the liver's blood supply; checkpoint-inhibitor immunotherapy, medicines that release a brake on the immune system (they help fewer people with uveal melanoma than with skin melanoma); and clinical trials. Standard chemotherapy usually helps little.

What to Expect

For a nevus, the usual course is uneventful: eye exams with photographs, more often at first and then less often once the spot is clearly stable. Only a small minority of nevi ever change, which is why monitoring rather than treatment is the standard approach. For uveal melanoma, the outlook depends mainly on the tumor's size, location and genetic features and on whether it has spread when found. Iris melanomas are usually small, slow-growing and rarely spread. Survival is often described with a five-year relative survival rate, which compares people with the cancer to people without it. For melanoma confined to the eye, that rate is about 88%; when the cancer has already reached distant organs such as the liver, it is about 19%. These figures come from people treated years ago and cannot predict any one person's course. Uveal melanoma can return or spread many years after successful eye treatment, most often to the liver. Follow-up is therefore long term: eye exams if the eye was kept, plus liver blood tests and imaging. Visits are frequent at first, often every few months, and spread out over time, with the schedule set by the tumor's size, location and gene results. Vision in a treated eye can keep changing for months or years as radiation effects appear, and some of these problems, such as cataract, can be treated with surgery. Losing sight in one eye, or the eye itself, takes adjustment. Worry about the cancer coming back is common, and support from the care team, counselors or other survivors can make long-term follow-up easier to carry.

When to Seek Help

See an eye doctor if you notice blurred or distorted vision, a shadow or gap in your field of sight, new floaters or flashes of light, a dark spot on the iris that is new or growing, or a change in the shape of the pupil. These symptoms usually have other causes, but only an examination can tell. A sudden shower of new floaters, new flashes of light, or a shadow or curtain moving across your vision can mean retinal detachment, which a tumor, a biopsy or radiation can cause; this needs a same-day eye exam, because prompt repair helps protect vision. If you have been told you have a nevus, keep to the recommended monitoring schedule and report any change in vision in that eye. After treatment for uveal melanoma, tell your care team about new or worsening vision problems in the treated eye or any new, persistent symptom elsewhere in the body, rather than waiting for the next scheduled visit. During tebentafusp treatment, contact the care team right away for fever, chills, dizziness, severe nausea or trouble breathing after an infusion, since these can be signs of cytokine release syndrome.

Questions to Ask Your Doctor

  1. 1.Is this a nevus, a melanoma or another kind of growth, and how certain are you?
  2. 2.If we watch it, how often will I be examined, and what change would lead to treatment?
  3. 3.Which treatment gives me the best chance of keeping my eye and useful vision, and how might my sight change over the next few years?
  4. 4.Should the tumor's genes be tested, and how would the results change my follow-up?
  5. 5.What liver monitoring will I need, and for how long?

Last reviewed • Oct 2026

Educational content, not medical advice.